Oramed Pharmaceuticals Inc expected to post a loss of 12 cents a share - Earnings Preview

Oramed Pharmaceuticals

01/03/2024 21:58

* Oramed Pharmaceuticals Inc  ORMP.OQ   ORMP.O  is expected
to show a fall in quarterly revenue when it reports  results on
March 4 (estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Oramed Pharmaceuticals
Inc is
for a loss of 12 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Oramed
Pharmaceuticals Inc is $4.25​, above​ its last closing price
of $3.29. ​​​

This summary was machine generated March 1 at 21:58 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)